正大天晴康方PD-1單抗價格細節公佈：創新發展與患者長期獲益共贏
8月12日，正大天晴藥業集團(“正大天晴”)與康方生物(9926.HK)共同開發的PD-1單克隆抗體藥物安尼可®(通用名：派安普利單抗注射液)的定價方案和患者救助方案細則流出。
按照該定價方案，安尼可®每支價格為4,875元/100mg，在國產PD-1單抗中單位規格定價最高。安尼可®是全球首款採用 IgG1 亞型並進行 Fc 段改造的新型 PD-1 單抗，優化的結構使得安尼可®更強效，更安全(延伸閲讀：為什麼説派安普利單抗是強效更安全的新型PD-1單抗)。正大天晴康方基於充分的市場研究後，制定出該高單位規格定價，是基於安尼可®在藥效和安全性方面和同類產品相比具有強大的競爭力和明顯的差異化特徵，同時為2022年安尼可®其他大適應症進入醫保做好了準備。
根據北京康盟慈善基金會消息，安尼可的患者救助方案具體為：首輪救助方案採取2+1模式，即患者購買使用2個週期(4支)後，贈送1個週期(2支)；後續救助方案為2+N，即再次購買使用2個週期(4支)後，該患者的後續用藥將全部贈送，直至疾病出現進展(PD)，但總用藥時間不超過24個月。
按照該定價方案和患者救助方案，首年安尼可®治療費用為39,000元，該費用與信迪利單抗慈善後費用相當。同時，以2年最長用藥時間計，安尼可®年治療費用僅為19,500元，這也為能從安尼可治療中長期獲益的患者真正帶來了最大的優惠。
對於上述價格方案，正大天晴、中國生物製藥和康方生物共同表示，安尼可®的定價和救助方案，在以患者獲得最大利益為中心的前提下，根據產品在療效和安全性方面的優勢實現差異化定價，也兼顧了目前PD-1單抗市場的競爭格局和中國生物醫藥產業創新發展的需求。“我們期待實現‘讓患者最大獲益與產業和企業的創新發展’共贏的良好局面。”三方共同表示。
同時，安尼可®聯合安羅替尼治療的“雙安組合”，未來前景可期。該聯合療法已經開展了包括一線治療非小細胞肺癌、肝癌等多項適應症的研究，這些臨牀研究的結果充分顯示了安尼可®和安羅替尼兩個同類最佳的藥物聯用，有望為患者帶來更好的醫療方案和臨牀獲益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
